SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?


To: Frank Brisebois who wrote (8160)7/20/1999 4:12:00 PM
From: Nick  Respond to of 9523
 
Pharmaceutical stocks good for the long haul
Potential for Alzheimer's vaccine spurs

faithhttp://cbs.marketwatch.com/archive/19990720/news/current/analyst.htx?source=blq/yhoo&dist=yhoo

Nick



To: Frank Brisebois who wrote (8160)7/20/1999 4:26:00 PM
From: B.REVERE  Read Replies (1) | Respond to of 9523
 
Gruntal's target is a little higher, about 35% higher.

Pfizer Inc. Reiterated 'Strong Buy' at Gruntal

Bloomberg News
July 20, 1999, 8:39 a.m. PT
Princeton, New Jersey, July 20 (Bloomberg Data) -- Pfizer Inc. (PFE US)
was reiterated ''strong buy'' by analyst David F. Saks at Gruntal & Co.
The 12-month target price is $59.00 per share.

More News: PFE